Medgenics Inc Directors Dealings (0646Z)
01 2월 2014 - 3:10AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 0646Z
Medgenics Inc
31 January 2014
Press Release 31 January 2014
Directors Dealings
Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the
developer of Biopump(TM) , a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, announces that, on 29 January 2014, it was
informed by Andrew Pearlman, a Director of the Company who retired
as CEO in September 2013, that he exercised options under a a
personal stock trading plan established in accordance with both the
guidelines established by Rule 10b5-1 under the U.S. Securities and
Exchange Act of 1934, as amended, and the AIM Rules for Companies
as well as the Company's policies with respect to insider sales. On
29 January 2014, Dr. Pearlman exercised options for 500 shares of
common stock at an exercise price of US$3.14 per share and sold the
same number of shares at a price of US$7.50 per share. Dr. Pearlman
also informed the Company on 30 January 2014 that he exercised
options on that day for 24,500 shares at an exercise price of
US$3.14 per share and sold the same number of shares of common
stock at a price of US$7.50 per share.
The stock was sold for personal financial planning purposes
including the payment of taxes in connection with the exercise of
stock options. Following these option exercises and sales, Dr.
Pearlman owns 42,375 shares of common stock representing
approximately 0.2 per cent of the issued share capital. Dr.
Pearlman also has the right to purchase up to 1,075,968 shares of
common stock pursuant to warrants and options previously granted
(in aggregate Dr. Pearlman's shares of common stock, warrants, and
options represent 1,118,343 shares of common stock which represent
approximately 6.0 per cent of the issued share capital).
This announcement is being made pursuant to the London Stock
Exchange's AIM Rules for Companies admitted to trading on the AIM
market.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis, among others. For more information,
please visit www.medgenics.com.
Contacts:
Medgenics, Inc.
John Leaman, CFO
john.leaman@medgenics.com
Abchurch Communications
Joanne Shears / Jamie Hooper
/ Harriet Rae
harriet.rae@abchurch-group.com +44 207 398 7718
Oriel Securities (NOMAD & Broker)
Jonathan Senior / Giles Balleny +44 207 710 7617
-Ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUARWRSNAAOAR
Medgenics(Regs) (LSE:MEDG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medgenics(Regs) (LSE:MEDG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024